Get started
Author

Natalie J. Rath

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
2017 · Silvio Danese, Séverine Vermeire, et al. · Gut · 181
PDF
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
2021 · Silvio Danese, Maria Klopocka, et al. · Clinical Gastroenterology and Hepatology · 102
PDF
Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)
2010 · Robert M. Ward, Brinda Tammara, et al. · European Journal of Clinical Pharmacology · 70
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
2025 · David Fiorentino, Aaron R Mangold, et al. · The Lancet · 62
A Multicenter, Randomized, Open-Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease
2010 · Robert M. Ward, Gregory L. Kearns, et al. · The Journal of Clinical Pharmacology · 33
Pharmacodynamics and Safety of Pantoprazole in Neonates, Preterm Infants, and Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease
2010 · Jaroslaw Kierkus, Wanda Furmaga-Jablonska, et al. · Digestive Diseases and Sciences · 26
Clinical Results From a Randomized, Double-Blind, Dose-Ranging Study of Pantoprazole in Children Aged 1 Through 5 Years With Symptomatic Histologic or Erosive Esophagitis
2010 · Robert Baker, V.Marc Tsou, et al. · Clinical Pediatrics · 25
Studies on the effect of D-penicillamine, gold thioglucose and methotrexate on streptococcal cell wall arthritis.
1986 · S C Ridge, N Rath, et al. · PubMed · 23
Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study
2020 · Srividya Neelakantan, Barry Oemar, et al. · Clinical Pharmacology in Drug Development · 21
Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month through <6 Years with Gastro-Oesophageal Reflux Disease
2011 · Brinda K. Tammara, Janice E. Sullivan, et al. · Clinical Pharmacokinetics · 20
Methotrexate suppresses passive adjuvant arthritis: studies on the metabolism of methotrexate in mononuclear cells derived from normal and adjuvant arthritic rats.
1988 · S C Ridge, K M Ferguson, et al. · PubMed · 13
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro‐oesophageal reflux disease and a history of erosive oesophagitis
2007 · D. HOGAN, V. PRATHA, et al. · Alimentary Pharmacology & Therapeutics · 8
PDF
764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders
2016 · Silvio Danese, Severine Vermeire, et al. · Gastroenterology · 7
Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders
2016 · Silvio Danese, Séverine Vermeire, et al. · 7
M1909 Randomized, Double-Blind Clinical Outcomes, Safety, and Tolerability Study of Pantoprazole Delayed-Release Granules in Children Aged 1 to 5 Years with Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)
2009 · Gail M. Comer, Robert D. Baker, et al. · Gastroenterology · 4
Pharmacokinetics of Two Dose Levels of Pantoprazole Sodium Delayed-Release Granules for Oral Suspension in Infants Aged 1 Through 11 Months with a Presumed Diagnosis of GERD
2008 · Brinda Tammara, Janice Sullivan, et al. · The American Journal of Gastroenterology · 3
M1908 Pharmacodynamics (PD) and Safety of Pantoprazole Delayed-Release Granules in Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD)
2009 · Gail M. Comer, Jaroslaw Kierkus, et al. · Gastroenterology · 2
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
2026 · Ruth Ann Vleugels, Elena Peeva, et al. · The Journal of Rheumatology · 1
PDF
1027 Safety, Tolerability, and Efficacy of Anti-tl1a Antibody Pf-06480605 in Treatment of Ulcerative Colitis: the Open-label, Multicenter, Phase 2a Tuscany Study
2020 · Silvio Danese, Maria Klopocka, et al. · Gastroenterology · 1
A phase 1 study of PF-07242813, an anti-CD1a antibody, in healthy participants and in patients with atopic dermatitis
2026 · Spencer I. Danto, Ruolun Qiu, et al. · JID Innovations
PDF
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
2020 · S Danese, M Klopocka, et al. · Journal of Crohn s and Colitis
Pharmacokinetics of Single and Multiple Doses of Pantoprazole in Adolescents with GERD
2008 · Brinda Tammara, Robert Ward, et al. · The American Journal of Gastroenterology
Comparison of Pentagastrin-Stimulated Maximum Acid Output in Patients with a History of Erosive Esophagitis Treated with 40 mg of Oral Pantoprazole Granules or Tablets
2006 · Vijay Pratha, Daniel Hogan, et al. · The American Journal of Gastroenterology
Works count: 23
Citation count: 609
H-index: 11
I10-index: 11
Year
Topic
Type